Mechanistic and inhibition studies on isocitrate dehydrogenase 1
<p>Genes encoding for IDH1 and IDH2 are frequently mutated in multiple cancer types including gliomas and AML. IDH variants, notably R132H IDH1, result in a gain-offunction leading to substantially enhanced production of the ‘oncometabolite’, 2- hydroxyglutarate. Drug development by pharmaceut...
Հիմնական հեղինակ: | Liu, S |
---|---|
Այլ հեղինակներ: | Schofield, C |
Ձևաչափ: | Թեզիս |
Լեզու: | English |
Հրապարակվել է: |
2019
|
Նմանատիպ նյութեր
-
The studies on the mechanism and inhibition of Isocitrate Dehydrogenases
: Liu, X
Հրապարակվել է: (2022) -
Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
: Li Su, և այլն
Հրապարակվել է: (2020-04-01) -
How robust are the data in vorasidenib for isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutant low-grade glioma?
: Eric T Wong
Հրապարակվել է: (2023-01-01) -
Highlighting the mechanistic role of Olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (mIDH1) in cancer therapy
: Elliasu Y. Salifu, և այլն
Հրապարակվել է: (2022-01-01) -
Differentiating inhibition selectivity and binding affinity of isocitrate dehydrogenase 1 variant inhibitors
: Liu, S, և այլն
Հրապարակվել է: (2023)